GSM5359433
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.480
- INTERFERON_ALPHA_RESPONSE+0.480
- INTERFERON_GAMMA_RESPONSE+0.450
- MITOTIC_SPINDLE+0.350
- IL6_JAK_STAT3_SIGNALING+0.310
- INFLAMMATORY_RESPONSE+0.310
- COMPLEMENT+0.300
- IL2_STAT5_SIGNALING+0.290
- G2M_CHECKPOINT+0.200
- TNFA_SIGNALING_VIA_NFKB+0.110
Top 10 suppressed
- MYC_TARGETS_V1-0.490
- ANGIOGENESIS-0.440
- MYC_TARGETS_V2-0.420
- OXIDATIVE_PHOSPHORYLATION-0.410
- FATTY_ACID_METABOLISM-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- GLYCOLYSIS-0.390
- PANCREAS_BETA_CELLS-0.390
- CHOLESTEROL_HOMEOSTASIS-0.380
- MTORC1_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313132 | — | D | 0.899 |
| 2 | AUR-AF95-TTP1-A-1-0-R-A741-41 | — | D | 0.887 |
| 3 | AUR-AG0J-TTP1-A-1-0-R-A741-41 | — | D | 0.886 |
| 4 | AUR-AFEA-TTP1-A-1-0-R-A741-41 | — | D | 0.858 |
| 5 | SRR5088892 | — | — | 0.856 |
| 6 | SRR12696760 | — | — | 0.852 |
| 7 | SRR5088835 | — | — | 0.847 |
| 8 | TCGA-E9-A2JT-01A-22R-A18M-07 | — | D | 0.846 |
| 9 | DRR168597 | — | — | 0.839 |
| 10 | 30608f63-2604-489c-bf96-09e56acfe912 | — | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.110 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.070 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.050 | Inavolisib | — uncovered |
| APOPTOSIS | 0.030 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |